글로벌 B형 간염 감염 시장 – 산업 동향 및 2031년까지의 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Pharmaceutical Global Hepatitis B Infection Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 B형 간염 감염 시장 – 산업 동향 및 2031년까지의 예측

  • Pharmaceutical
  • Published Report
  • Nov 2024
  • Global
  • 350 Pages
  • 테이블 수: 255
  • 그림 수: 32
지금 구매 지금 구매

Global Hepatitis B Infection Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2024 –2031
Diagram 시장 규모(기준 연도)
 USD 12.11 Billion
Diagram 시장 규모(예측 연도)
 USD 18.21 Billion
Diagram 연평균 성장률
 %
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
잠금 해제 요청

>글로벌 B형 간염 감염 시장, 유형별(만성 및 급성), 치료별(백신, 항바이러스 약물, 면역 조절 약물 및 수술) - 2031년까지의 산업 동향 및 예측      

B형 간염 감염 시장

B형 간염 감염 시장 분석 및 통찰력

Data Bridge Market Research에 따르면 글로벌 B형 간염 감염 시장은 2023년 121억 1,000만 달러에서 2031년 182억 1,000만 달러로 성장할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률 5.2%로 성장할 것으로 예상됩니다.

B형 간염 감염 시장B형 간염 감염 시장

보고서 메트릭

세부

예측 기간

2024년부터 2031년까지

기준 연도

2023

역사적 연도

2022 (2016-2021년까지 사용자 정의 가능)

양적 단위

매출 (USD) 10억

다루는 세그먼트

유형(만성 및 급성), 치료(백신, 항바이러스제 , 면역 조절제 및 수술)   

적용 국가

 미국, 캐나다 및 멕시코, 중국, 인도, 일본, 한국, 싱가포르, 태국, 말레이시아, 인도네시아, 호주, 베트남, 뉴질랜드, 대만, 필리핀 및 기타 아시아 태평양, 독일, 영국, 프랑스, ​​이탈리아, 스페인, 러시아, 네덜란드, 스위스, 벨기에, 스웨덴, 덴마크, 노르웨이, 핀란드, 폴란드 터키 및 기타 유럽, 남아프리카, 사우디 아라비아, 이집트, 쿠웨이트, 카타르, UAE, 오만, 바레인 및 기타 중동 및 아프리카, 브라질, 아르헨티나 및 기타 남미

시장 참여자 포함

 Gilead Sciences, Inc.(미국), GlaxoSmithKline plc(영국), Dynavax Technologies(미국), F. Hoffmann-La Roche Ltd(스위스), Bristol-Myers Squibb Company(미국), Merck Sharp and Dohme Corp.(미국), Novartis AG(스위스), Arrowhead Pharmaceuticals Inc.(미국), Arbutus Biopharma(캐나다), Teva Pharmaceuticals, Inc.(이스라엘), Zydus Pharmaceuticals(인도), Aurobindo Pharma(인도), Lupin Pharmaceuticals, Inc.(인도)

시장 정의

글로벌 B형 간염 감염 시장은 B형 간염 바이러스(HBV) 감염의 진단, 치료, 예방 및 관리에 중점을 둔 의료 분야를 말합니다. 이 시장은 백신, 항바이러스 약물, 진단 검사, 면역 조절제 및 급성 및 만성 B형 간염을 모두 다루는 치료제를 포함한 광범위한 제품과 서비스를 포함합니다. B형 간염은 HBV로 인해 발생하는 매우 전염성이 강한 간 질환으로 간경변, 간부전 및 간세포암과 같은 심각한 건강 합병증을 유발할 수 있습니다. 이 시장에는 첨단 치료 솔루션을 개발하기 위해 노력하는 제약 회사, 생명 공학 회사, 진단 서비스 제공업체, 의료 시설 및 연구 기관이 포함됩니다. 전 세계적으로 B형 간염의 유병률이 증가하고 있으며, 이에 대한 인식이 높아지고 확산을 억제하기 위한 정부 이니셔티브가 시장 성장의 주요 원동력입니다.

세계 B형 간염 감염 시장 동향.

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:      

Drivers

  • increasing Prevalence of Hepatitis B Infections ​​​​​​​

 The increasing prevalence of Hepatitis B infections serves as a significant driver in the global Hepatitis B infection market by creating a growing demand for effective diagnostic tools, vaccines, and antiviral treatments. As Hepatitis B is a major cause of liver diseases such as cirrhosis and liver cancer, the rising infection rates globally, particularly in regions with inadequate healthcare infrastructure, have heightened the need for prevention, management, and treatment options. The spread of chronic Hepatitis B infections, especially in low- and middle-income countries where awareness and vaccination programs are less established, further amplifies the market for immunization, antiviral therapies, and advanced diagnostic techniques. Also, pharmaceutical companies are investing in research and development of newer, more efficient antiviral drugs and vaccines to address the evolving strains of the virus. The rise in both acute and chronic cases, particularly in high-risk populations, has put pressure on healthcare systems to invest in improved diagnostics, vaccines, and antiviral therapies.

Restraints

  •  Side effects and drug resistance
  • Side effects and drug resistance serve as significant restraints in the global Hepatitis B infection market by limiting the effectiveness and long-term use of available therapies. Many antiviral drugs used to treat Hepatitis B can cause adverse effects such as fatigue, nausea, liver toxicity, and kidney damage, which can lead to poor patient adherence and treatment discontinuation. This not only hampers the success of treatment but also reduces the overall demand for certain medications. Furthermore, the development of drug-resistant strains of the Hepatitis B virus presents another major challenge, as it reduces the efficacy of current antiviral therapies and necessitates the constant development of new drugs. As resistance to existing treatments increases, it creates barriers for healthcare providers in managing the infection effectively, limiting the market's growth potential. These challenges contribute to hesitancy in prescribing long-term antiviral therapies, slowing the adoption of certain medications and thereby restraining market expansion

B형 간염 감염 시장

Opportunity

  •  Rising New Drug Releases and Increasing New Drug Permits for Hepatitis B

The hepatitis B market is experiencing significant growth, driven by several key factors including the rising number of new drug releases and an increase in new drug permits. The surge in drug approvals is partly a response to the persistent need for more effective antiviral therapies and vaccines to manage and potentially eradicate hepatitis B. This trend is evident from the increased investments in research and development by major pharmaceutical companies, which are focusing on innovative treatment options that offer improved efficacy, fewer side effects, and enhanced patient compliance. Additionally, advancements in drug delivery systems and the development of combination therapies have contributed to the expansion of the market. The growth in market share for hepatitis B drugs is also supported by the increasing global prevalence of the disease, particularly in regions with high infection rates such as Asia-Pacific and sub-Saharan Africa. As new therapies become available and the market becomes more competitive, financial growth is expected to be robust, with projections indicating a substantial increase in market value over the coming years. This growth is underpinned by rising healthcare expenditure, broader healthcare access, and heightened awareness about the importance of hepatitis B management. The market is likely to see continued expansion as new players enter the field, existing companies innovate, and healthcare systems around the world prioritize hepatitis B treatment.

Challenge

  •  The Cost of Hepatitis B Treatments is High

The high cost of hepatitis B treatments presents significant challenges for the market. One of the primary factors contributing to this challenge is the complexity of developing antiviral drugs and immunomodulators that effectively manage the virus without causing severe side effects. This complexity requires extensive research, clinical trials, and regulatory approvals, all of which drive up the price of the final product. Additionally, the ongoing nature of treatment for chronic hepatitis B means that patients often face long-term costs, which can be prohibitively expensive, particularly in regions with limited access to healthcare subsidies or insurance coverage.

Another challenge is the limited availability of generic versions of hepatitis B drugs. Many of the more effective treatments remain under patent protection, allowing pharmaceutical companies to maintain high prices. This lack of competition further exacerbates the financial burden on patients, healthcare systems, and governments. Moreover, the development of newer treatments, such as those aimed at complete viral eradication, is still in the early stages, with no immediate prospects for significantly lowering treatment costs in the near future.

  • 2022년 5월, B형 간염 재단에서 발표한 기사에 따르면, B형 간염을 앓고 있는 약 3억 명의 사람들 중 10%만이 진단을 받았고, 진단을 받은 사람 중 22%만이 항바이러스 치료를 받았습니다. 아프리카에서는 상황이 더욱 심각하여 만성 B형 간염 환자 중 2%만이 진단을 받았고 0.1%만이 치료를 받았습니다. 치료 에 대한 상당한 장벽 은 비용입니다 .

최근 개발 사항

  • 2024년 9월, 길리어드 사이언스와 제네시스 테라퓨틱스는 제네시스의 GEMS AI 플랫폼을 사용하여 새로운 소분자 치료법을 발견하고 개발하기 위한 전략적 협력을 발표했습니다. 길리어드는 이 파트너십을 통해 제품을 개발하고 상용화할 독점권을 얻었습니다.
  • 2024년 2월, GSK는 중증 천식에 대한 유망한 단일클론 항체인 AIO-001을 포함하여 Aiolos Bio 인수를 완료했습니다. GSK는 선불로 10억 달러를 지불했고, 이정표 지불로 최대 4억 달러를 지불하여 호흡기 생물학 포트폴리오를 확대했습니다.

글로벌 B형 간염 감염 시장 범위

  글로벌 B형 간염 감염 시장은 유형과 치료법을 기준으로 두 가지 주목할 만한 세그먼트로 분류됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

유형

  • 만성병 환자
  • 심각한

시장은 유형을 기준으로 만성형과 급성형으로 구분됩니다.

 치료

  • 백신
  •  항바이러스 약물
  • 면역 조절제 약물
  • 수술

치료법을 기준으로 시장은 백신, 항바이러스제, 면역 조절제, 수술 로 구분됩니다 .

B형 간염 감염 시장

글로벌 B형 간염 감염 시장 지역 분석/통찰력

글로벌 B형 간염 감염 시장은 유형과 치료에 따라 두 가지 주요 부문으로 분류됩니다. 

이 시장 보고서에서 다루는 국가는 미국, 캐나다 및 멕시코, 중국, 인도, 일본, 한국, 싱가포르, 태국, 말레이시아, 인도네시아, 호주, 베트남, 뉴질랜드, 대만, 필리핀, 기타 아시아 태평양 지역, 독일, 영국, 프랑스, ​​이탈리아, 스페인, 러시아, 네덜란드, 스위스, 벨기에, 스웨덴, 덴마크, 노르웨이, 핀란드, 폴란드, 터키, 기타 유럽 지역, 남아프리카, 사우디 아라비아, 이집트, 쿠웨이트, 카타르, UAE, 오만, 바레인, 기타 중동 및 아프리카 지역, 브라질, 아르헨티나, 기타 남미 지역입니다.

아시아 태평양 지역은 B형 간염에 대한 복합 치료법의 개발과 B형 간염 감염에 대한 기업의 전략적 이니셔티브로 인해 시장을 주도할 것으로 예상됩니다. 

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제와 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

B형 간염 감염 시장

경쟁 환경 및 글로벌 B형 간염 감염 시장 역학 점유율 분석

글로벌 B형 간염 감염 시장 역학 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭 및 폭, 응용 프로그램 우세 및 제품 유형 수명선 곡선입니다. 제공된 위의 데이터 포인트는 회사가 시장에 집중하는 것과만 관련이 있습니다.

시장에서 활동하는 주요 시장 주체로는 Gilead Sciences, Inc.(미국), GlaxoSmithKline plc(영국), Dynavax Technologies(미국), F. Hoffmann-La Roche Ltd(스위스), Bristol-Myers Squibb Company(미국), Merck Sharp and Dohme Corp.(미국), Novartis AG(스위스), Arrowhead Pharmaceuticals Inc.(미국), Arbutus Biopharma(캐나다), Teva Pharmaceuticals, Inc.(이스라엘), Zydus Pharmaceuticals(인도), Aurobindo Pharma(인도), Lupin Pharmaceuticals, Inc.(인도) 등이 있습니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL HEPATITIS B INFECTION MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 THERAPEUTICS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTAL ANALYSIS

4.2 PORTER FIVE FORCES

5 GLOBAL HEPATITIS B INFECTION MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION

5.2 NORTH AMERICA REGULATORY SCENARIO

5.3 EUROPE REGULATORY SCENARIO

5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO

5.5 SOUTH AMERICA REGULATORY SCENARIO

6 PIPELINE ANALYSIS

7 EPIDEMILIOGY

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS

8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS

8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B

8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION

8.2 RESTRAINTS

8.2.1 SIDE EFFECTS AND DRUG RESISTANCE

8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION

8.3 OPPORTUNITY

8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B

8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION

8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS

8.4 CHALLENGES

8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH

8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS

9 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE

9.1 OVERVIEW

9.2 CHRONIC

9.3 ACUTE

10 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 VACCINE

10.2.1 HOSPITAL PHARMACIES

10.2.2 DRUGS STORES AND RETAIL PHARMACIES

10.2.3 ONLINE PHARMACIES

10.3 ANTIVIRAL DRUGS

10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF)

10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF)

10.3.3 ENTECAVIR

10.3.4 OTHERS

10.4 IMMUNE MODULATOR DRUGS

10.4.1 PEGYLATED INTERFERON

10.4.2 INTERFERON ALPHA

10.5 SURGERY

11 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S

11.2.2 CANADA

11.2.3 MEXICO

11.3 SOUTH AMERICA

11.3.1 BRAZIL

11.3.2 ARGENTINA

11.3.3 REST OF SOUTH AMERICA

11.4 MIDDLE EAST AND AFRICA

11.4.1 SOUTH AFRICA

11.4.2 SAUDI ARABIA

11.4.3 EGYPT

11.4.4 KUWAIT

11.4.5 QATAR

11.4.6 U.A.E

11.4.7 OMAN

11.4.8 BAHRAIN

11.4.9 REST OF MIDDLE EAST AND AFRICA

11.5 ASIA-PACIFIC

11.5.1 CHINA

11.5.2 INDIA

11.5.3 INDONESIA

11.5.4 JAPAN

11.5.5 VIETNAM

11.5.6 PHILIPPINES

11.5.7 THAILAND

11.5.8 SOUTH KOREA

11.5.9 AUSTRALIA

11.5.10 SINGAPORE

11.5.11 MALAYSIA

11.5.12 NEW ZEALAND

11.5.13 TAIWAN

11.5.14 REST OF ASIA-PACIFIC

11.6 EUROPE

11.6.1 GERMANY

11.6.2 U.K

11.6.3 TURKEY

11.6.4 RUSSIA

11.6.5 SPAIN

11.6.6 ITALY

11.6.7 SWEDEN

11.6.8 BELGIUM

11.6.9 POLAND

11.6.10 FRANCE

11.6.11 SWITZERLAND

11.6.12 NETHERLANDS

11.6.13 NORWAY

11.6.14 DENMARK

11.6.15 FINLAND

11.6.16 REST OF EUROPE

12 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 GILEAD SCIENCES, INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 GLAXOSMITHKLINE PLC

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.3 DYNAVAX TECHNOLOGIES CORPORATION

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 F. HOFFMAN-LA ROCHE LTD.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 BRISTOL-MYERS SQUIBB COMPANY

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ARROWHEAD PHARMACEUTICALS, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ARBUTUS BIOPHARMA

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT UPDATES

14.8 AUROBINDO PHARMA

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT UPDATES

14.9 LUPIN PHARMACEUTICALS, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT UPDATES

14.1 MERCK & CO., INC.,

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 NOVARTIS AG

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 TEVA PHARMACEUTICAL INDUSTRIES

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 ZYDUS PHARMACEUTICALS, INC.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 REVENUE

14.13.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

표 목록

TABLE 1 GLOBAL CLINICAL TRIAL AND PIPELINE A-LYSIS AS PER THE COMPANY

TABLE 2 DISTRIBUTION OF PRODUCTS OR PROJECTS BY PHASE

TABLE 3 COUNTRY WISE EPIDEMIOLOGY FOR HEPATITIS B

TABLE 4 COST OF HEPATITIS B MEDICATIONS: BRAND VS. GENERIC PRICES

TABLE 5 GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL CHRONIC IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL ACUTE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL VACCINE IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL SURGERY IN HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL HEPATITIS B INFECTION MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 17 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 18 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 19 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 20 NORTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 21 NORTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 22 NORTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 23 U.S. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 24 U.S. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 25 U.S. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 26 U.S. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 27 U.S. VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 28 CANADA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 29 CANADA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 30 CANADA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 31 CANADA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 32 CANADA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 33 MEXICO HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 34 MEXICO HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 35 MEXICO ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 36 MEXICO IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 37 MEXICO VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 38 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 39 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 40 SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 41 SOUTH AMERICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 42 SOUTH AMERICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 43 SOUTH AMERICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 44 BRAZIL HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 45 BRAZIL HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 46 BRAZIL ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 47 BRAZIL IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 48 BRAZIL VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 49 ARGENTINA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 50 ARGENTINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 51 ARGENTINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 52 ARGENTINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 53 ARGENTINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 54 REST OF SOUTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 61 SOUTH AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 62 SOUTH AFRICA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 63 SOUTH AFRICA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 64 SOUTH AFRICA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 65 SOUTH AFRICA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 66 SAUDI ARABIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 67 SAUDI ARABIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 68 SAUDI ARABIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 69 SAUDI ARABIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 70 SAUDI ARABIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 71 EGYPT HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 72 EGYPT HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 73 EGYPT ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 74 EGYPT IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 75 EGYPT VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 76 KUWAIT HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 77 KUWAIT HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 78 KUWAIT ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 79 KUWAIT IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 80 KUWAIT VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 81 QATAR HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 82 QATAR HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 83 QATAR ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 84 QATAR IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 85 QATAR VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 86 U.A.E HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 87 U.A.E HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 88 U.A.E ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 89 U.A.E IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 90 U.A.E VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 91 OMAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 92 OMAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 93 OMAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 94 OMAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 95 OMAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 96 BAHRAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 97 BAHRAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 98 BAHRAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 99 BAHRAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 100 BAHRAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 101 REST OF MIDDLE EAST AND AFRICA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 102 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 103 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 104 ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 105 ASIA-PACIFIC ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 106 ASIA-PACIFIC IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 107 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 108 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 109 CHINA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 110 CHINA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 111 CHINA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 112 CHINA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 113 INDIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 114 INDIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 115 INDIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 116 INDIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 117 INDIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 118 INDONESIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 119 INDONESIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 120 INDONESIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 121 INDONESIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 122 INDONESIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 123 JAPAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 124 JAPAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 125 JAPAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 126 JAPAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 127 JAPAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 128 VIETNAM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 129 VIETNAM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 130 VIETNAM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 131 VIETNAM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 132 VIETNAM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 133 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 134 PHILIPPINES HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 135 PHILIPPINES ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 136 PHILIPPINES IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 137 PHILIPPINES VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 138 THAILAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 139 THAILAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 140 THAILAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 141 THAILAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 142 THAILAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 143 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 144 SOUTH KOREA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 145 SOUTH KOREA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 146 SOUTH KOREA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 147 SOUTH KOREA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 148 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 149 AUSTRALIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 150 AUSTRALIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 151 AUSTRALIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 152 AUSTRALIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 153 SINGAPORE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 154 SINGAPORE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 155 SINGAPORE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 156 SINGAPORE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 157 SINGAPORE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 158 MALAYSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 159 MALAYSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 160 MALAYSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 161 MALAYSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 162 MALAYSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 163 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 164 NEW ZEALAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 165 NEW ZEALAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 166 NEW ZEALAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 167 NEW ZEALAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 168 TAIWAN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 169 TAIWAN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 170 TAIWAN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 171 TAIWAN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 172 TAIWAN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 173 REST OF ASIA-PACIFIC HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 174 EUROPE HEPATITIS B INFECTION MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 175 EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 176 EUROPE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 177 EUROPE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 178 EUROPE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 179 EUROPE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 180 GERMANY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 181 GERMANY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 182 GERMANY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 183 GERMANY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 184 GERMANY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 185 U.K. HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 186 U.K. HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 187 U.K. ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 188 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 189 U.K. IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 190 TURKEY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 191 TURKEY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 192 TURKEY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 193 TURKEY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 194 TURKEY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 195 RUSSIA HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 196 RUSSIA HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 197 RUSSIA ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 198 RUSSIA IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 199 RUSSIA VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 200 SPAIN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 201 SPAIN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 202 SPAIN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 203 SPAIN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 204 SPAIN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 205 ITALY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 206 ITALY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 207 ITALY ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 208 ITALY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 209 ITALY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 210 SWEDEN HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 211 SWEDEN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 212 SWEDEN ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 213 SWEDEN IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 214 SWEDEN VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 215 BELGIUM HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 216 BELGIUM HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 217 BELGIUM ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 218 BELGIUM IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 219 BELGIUM VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 220 POLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 221 POLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 222 POLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 223 POLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 224 POLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 225 FRANCE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 226 FRANCE HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 227 FRANCE ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 228 FRANCE IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 229 FRANCE VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 230 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 231 SWITZERLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 232 SWITZERLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 233 SWITZERLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 234 SWITZERLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 235 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 236 NETHERLANDS HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 237 NETHERLANDS ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 238 NETHERLANDS IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 239 NETHERLANDS VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 240 NORWAY HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 241 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 242 NORWAY HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 243 NORWAY IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 244 NORWAY VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 245 DENMARK HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 246 DENMARK HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 247 DENMARK ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 248 DENMARK IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 249 DENMARK VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 250 FINLAND HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 251 FINLAND HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 252 FINLAND ANTIVIRAL DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 253 FINLAND IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY TREATMENT, 2022-2031 (USD MILLION)

TABLE 254 FINLAND VACCINE, ANTIVIRAL DRUGS, IMMUNE MODULATOR DRUGS IN HEPATITIS B INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 255 REST OF EUROPE HEPATITIS B INFECTION MARKET, BY TYPE, 2022-2031 (USD MILLION)

그림 목록

FIGURE 1 GLOBAL HEPATITIS B INFECTION MARKET: SEGMENTATION

FIGURE 2 GLOBAL HEPATITIS B INFECTION MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL HEPATITIS B INFECTION MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL HEPATITIS B INFECTION MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL HEPATITIS B INFECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL HEPATITIS B INFECTION MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL HEPATITIS B INFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL HEPATITIS B INFECTION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL HEPATITIS B INFECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL HEPATITIS B INFECTION MARKET: SEGMENTATION

FIGURE 11 ASIA PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL HEPATITIS B INFECTION MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 12 TWO SEGMENTS COMPRISE THE GLOBAL HEPATITIS B INFECTION MARKET, BY TYPE

FIGURE 13 EXECUTIVE SUMMARY

FIGURE 14 STRATEGIC DECISIONS

FIGURE 15 GLOBAL HEPATITIS B INFECTION MARKET

FIGURE 16 CHRONIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL HEPATITIS B INFECTION MARKET IN 2024 & 2031

FIGURE 17 ASIA PACIFIC IS THE FASTEST GROWING MARKET FOR THE GLOBAL HEPATITIS B INFECTION MARKET IN 2024 & 2031

FIGURE 18 DROC ANALYSIS

FIGURE 19 BURDEN OF HBV INFECTION IN THE GENERAL POPULATION BY WHO REGION, 2019

FIGURE 20 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, 2023

FIGURE 21 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 22 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 23 GLOBAL HEPATITIS B INFECTION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, 2023

FIGURE 25 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, 2024-2031 (USD MILLION)

FIGURE 26 GLOBAL HEPATITIS B INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)

FIGURE 27 GLOBAL HEPATITIS B INFECTION MARKET BY TREATMENT, LIFELINE CURVE

FIGURE 28 GLOBAL HEPATITIS B INFECTION MARKET, SNAPSHOT

FIGURE 29 GLOBAL HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 30 NORTH AMERICA HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 31 EUROPE HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)

FIGURE 32 ASIA-PACIFIC HEPATITIS B TREATMENT MARKET: COMPANY SHARE 2023 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

In 2023, the market value for the Global hepatitis B treatment Market was USD 12,108.29 million.
The Global hepatitis B treatment Market is expected to grow at a CAGR of 5.2% during the forecast period of 2024 to 2031.
Some of the major factors driving the market growth are increasing prevalence of hepatitis b infections, technological advancements in diagnostics, and development of combination therapies for hepatitis b are expected to further cushion the market growth during the forecast period.
Some of the major market players operating in this market are include Gilead Sciences, Inc. (U.S.), GlaxoSmithKline plc (UK), Dynavax Technologies (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (U.S.), Merck Sharp and Dohme Corp. (U.S.), Novartis AG (Switzerland), Arrowhead Pharmaceuticals Inc. (U.S.), Arbutus Biopharma (Canada), Teva Pharmaceuticals, Inc. (Israel), Zydus Pharmaceuticals (India), Aurobindo Pharma (India), Lupin Pharmaceuticals, Inc. (India) among others.
Global hepatitis B treatment Market is categorized into two notable segments which are based on the type and treatment.

관련 페이지 탐색

Banner